目的 探讨连花清咳片联合复方甲氧那明胶囊治疗慢性咳嗽痰热壅肺证的临床疗效。方法 选取2024年1月—2025年1月眉山市中医医院收治的110例慢性咳嗽痰热壅肺证患者，采用随机数字表法将患者分为对照组和治疗组，每组各55例。对照组饭后口服复方甲氧那明胶囊，2粒/次，3次/d。治疗组患者在对照组治疗基础上口服连花清咳片，4片/次，3次/d。两组患者均连续治疗8 d。对比两组的临床疗效、临床症状改善情况、肺功能指标、生活质量、血清炎性细胞因子。结果 治疗组的总有效率94.55%高于对照组80.00%（P＜0.05）。治疗组的咳嗽缓解时间、咳嗽消失时间均短于对照组（P＜0.05）。治疗后，两组的日间咳嗽症状积分、夜间咳嗽症状积分均降低（P＜0.05），且治疗组患者的咳嗽症状积分低于对照组（P＜0.05）。治疗后，两组一秒钟用力呼气容积（FEV1）、FEV1与用力肺活量（FVC）比值均升高（P＜0.05），且治疗组的FEV1、FEV1/FVC比值高于对照组（P＜0.05）。治疗后，两组中文版莱斯特咳嗽问卷（LCQ-MC）评分升高，简易咳嗽程度评分量表（CET）评分降低（P＜0.05），且治疗组LCQ-MC评分高于对照组，CET评分低于对照组（P＜0.05）。治疗后，两组血清肿瘤坏死因子-α（TNF-α）、白细胞介素-4（IL-4）、降钙素原（PCT）、白细胞介素-17（IL-17）水平均下降（P＜0.05），且治疗组血清TNF-α、IL-4、PCT、IL-17水平低于对照组（P＜0.05）。结论 连花清咳片联合复方甲氧那明胶囊治疗慢性咳嗽痰热壅肺证可显著提高总有效率，缓解咳嗽症状，改善肺通气功能和咳嗽相关生活质量，降低炎症因子水平。

Objective To explore the clinical efficacy of Lianhua Qingke Capsules combined with Compound Methoxyphenamine Capsules in treatment of chronic cough with phlegm-heat stagnation syndrome. Methods 110 Patients with chronic cough and phlegm-heat stagnation syndrome admitted to Meishan Traditional Chinese Medicine Hospital from January 2024 to January 2025 were selected. The patients were divided into control group and treatment group using a random number table method, with 55 patients in each group. The control group took Compound Methoxypheniramine Capsules orally after meals, 2 capsules/time, 3 times daily. The treatment group took Lianhua Qingke Tablets orally on the basis of the control group's treatment., 4 tablets/time, 3 times daily. Two groups of patients were treated continuously for 8 d. The clinical efficacy, clinical symptom improvement, lung function indicators, quality of life, and serum inflammatory cytokines of the two groups were compared. Results The total effective rate 94.55% of the treatment group was higher than 80.00% of the control group (P < 0.05). The cough relief time and cough disappearance time of the treatment group were shorter than those of the control group (P < 0.05). After treatment, the daytime cough symptom score and nighttime cough symptom score of two groups decreased (P < 0.05), and the cough symptom score of the treatment group was lower than that of the control group (P < 0.05). After treatment, the forced expiratory volume in one second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) increased in two groups (P< 0.05), and the FEV1 and FEV1/FVC ratio in the treatment group were higher than those in the control group (P < 0.05). After treatment, the Chinese version of the Leicester Cough Questionnaire (LCQ-MC) scores of two groups increased, while the Simplified Cough Severity Scale (CET) scores decreased (P < 0.05), and the LCQ-MC score of the treatment group was higher than that of the control group, while the CET score was lower than that of the control group (P<0.05). After treatment, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), procalcitonin (PCT), and interleukin-17 (IL-17) in two groups decreased (P < 0.05), and the serum levels of TNF-α, IL-4, PCT, and IL-17 in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Lianhua Qingke Tablets and Compound Methoxyphenamine Capsules can significantly improve total effective rate in treatment of chronic cough with phlegm heat obstructing the lungs, alleviate cough symptoms, improve lung ventilation function and cough related quality of life, and reduce inflammatory factors levels.

眉山市科学技术计划项目（kjzd202242）